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A B S T R A C T
Background
Heavy menstrual bleeding (HMB) is an important cause of ill health in premenopausal women. Although surgery is often used as a
treatment, a range of medical therapies are also available. Nonsteroidal anti-inflammatory drugs reduce prostaglandin levels which are
elevated in women with excessive menstrual bleeding and also may have a beneficial effect on dysmenorrhoea.
Objectives
The primary objective of this review was to investigate the effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs) in achieving
a reduction in menstrual blood loss in women of reproductive years HMB.
Search strategy
We searched the Cochrane Menstrual Disorders & Subfertility Group trials register (searched 6 April 2004), the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 1, 2004), MEDLINE (1966 to April 2004), EMBASE (1985
to April 2004), CINAHL (1982 to April 2004), and Current Contents (1993 to April 2004) and reference lists of articles. We also
contacted manufacturers and researchers in the field.
Selection criteria
The inclusion criteria were randomised comparisons of individual NSAIDs with either each other, placebo or other medical treatments
in women with regular heavy periods measured either objectively or subjectively and with no pathological or iatrogenic (treatment
induced) causes for their heavy menstrual blood loss.
Data collection and analysis
Sixteen RCTs were identified that fulfilled the inclusion criteria for this review and data were extracted independently. Odds ratios
for dichotomous outcomes and weighted mean differences for continuous outcomes were estimated from the data of nine trials. The
results of the remaining seven crossover trials with data unsuitable for pooling were described in the Other Data section.
Main results
As a group, NSAIDs were more effective than placebo at reducing heavy menstrual bleeding but less effective than either tranexamic
acid or danazol. Treatment with danazol caused a shorter duration of menstruation and more adverse events than NSAIDs but this did
not appear to affect the acceptability of treatment. There were no statistically significant differences between NSAIDs and the other
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treatments (oral luteal progestogen, ethamsylate, progesterone releasing intra-uterine system (IUS), oral contraceptive pill (OCC)) but
most studies were underpowered. There was no evidence of a difference between the individual NSAIDs (naproxen and mefenamic
acid) in reducing HMB.
Authors’ conclusions
NSAIDs reduce HMB when compared with placebo but are less effective than either tranexamic acid or danazol. However, adverse
events are more severe with danazol therapy. In the limited number of small studies suitable for evaluation, no significant difference in
efficacy was demonstrated between NSAIDs and other medical treatments such as oral luteal progestogen, ethamsylate, OCC or IUS.
P L A I N L A N G U A G E S U M M A R Y
NSAIDs help reduce heavy menstrual bleeding but tranexamic acid or danazol work better.
Women seek help for heavy menstrual bleeding (HMB) when it impacts on their quality of life although the menstrual loss can be
assessed objectively. Levels of prostaglandin (naturally occurring fatty acids) are higher in women with heavy menstrual bleeding and
are reduced by nonsteroidal anti-inflammatory drugs (NSAIDs). The review of trials found that NSAIDs are effective in reducing
HMB but danazol and tranexamic acid are more effective. Danazol caused a shorter duration of bleeding and more adverse effects than
NSAIDs but this did not stop women using it. These results are based on a small number of underpowered trials.
B A C K G R O U N D
Excessively heavy menstrual bleeding (menorrhagia) is an impor-
tant cause of ill health in women. One in 20 women aged 30 to
49 consult their general practitioner (GP) each year with heavy
menstrual bleeding (Vessey 1992) and it accounts for 12% of all
gynaecology referrals in the UK (Bradlow 1992).
Heavy menstrual bleeding is objectively defined as greater than,
or equal to, 80 mls blood loss per menstrual cycle (Cole 1971;
Hallberg 1966) but it is the woman’s perception of her own men-
strual loss which is the key determinant in her referral and indeed
subsequent treatment. Many factors can cause abnormal menstru-
ation (coagulation disorders, endocrine disorders, uterine abnor-
malities and other pelvic diseases) and these disorders are usu-
ally considered before decisions are made about treatment. Eighty
per cent of women treated for heavy menstrual bleeding have no
anatomical pathology and over a third of the women undergoing
hysterectomies for excessive blood loss have normal uteri removed
(Clarke 1995;Gath 1982).Hencemedical therapy, with the avoid-
ance of possibly unnecessary surgery, is an attractive alternative.
A wide variety of medications are used to reduce heavy men-
strual bleeding (HMB). A rationale for the use of non-steroidal
anti-inflammatory drugs is given by the accumulation of data
suggesting a role for the prostaglandins in the pathogenesis of
HMB (Hagenfeldt 1987). The endometrium of women with ex-
cessive menstrual bleeding has been found to have higher levels
of prostaglandin E2 and prostaglandin F2a when compared with
women with normal menses (Willman 1976). There is further ev-
idence of deranged haemostasis (abnormal clotting) as the ratio
of prostaglandin E2 to F2 (Smith 1981) and the ratio of prosta-
cyclin (prostaglandin I2) to thromboxane (Makarainen 1986) are
elevated. These substances are present both in the endometrium
and myometrium, although the exact mechanism by which the
excessive blood loss occurs remains speculative. Nonsteroidal anti-
inflammatory drugs (NSAIDs) reduce prostaglandin levels by in-
hibiting the enzyme cyclo-oxygenase (Rees 1987; Smith 1981).
In 1976, Anderson reported a reduction of menstrual blood loss
when mefenamic acid and flufenamic acid were taken during the
days of menstrual bleeding (Anderson 1976). Reduced menstrual
loss (assessed subjectively) has also been reported after treatment
with mefenamic acid (Wood 1980).
Individual NSAIDs used for the treatment of heavy menstrual
bleeding include mefenamic acid, naproxen, ibuprofen, flurbipro-
fen, meclofenamic acid, diclofenac, indomethacin and acetylsali-
cylic acid. It is usually assumed that there are no differences in clin-
ical efficacy between individual prostaglandin inhibitors, although
there are individual women who seem to respond well to one agent
but less well to another. This assumption has been tested in the
review with the inclusion of individual NSAID comparisons for
the treatment of HMB. NSAIDs also can have a beneficial effect
on dysmenorrhoea, a symptom often related to heavy menstrual
bleeding. Side effects of treatment, especially gastro-intestinal ef-
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fects, are variable in frequency but are not usually severe.
O B J E C T I V E S
Todetermine the effectiveness ofNSAIDs in achieving a reduction
inmenstrual blood loss in women of reproductive years with heavy
menstrual bleeding.
We wished to test the following hypotheses:
(1) Treatment with NSAIDs is more effective than placebo in
reducing menstrual blood loss.
(2) Treatment with NSAIDs is more effective than other medical
therapies (anti-fibrinolytics, danazol, hormone treatment, LHRH/
GNRH analogues) in reducing menstrual blood loss.
(3) Individual NSAIDs have similar efficacy in reducingmenstrual
blood loss.
(4) Treatment with NSAIDs is associated with a lower incidence
of adverse events and higher adherence and greater acceptability
than other medical therapies.
(5) Treatment with NSAIDs is a cost-effective method of treating
heavy menstrual bleeding.
(6) Treatment with NSAIDs leads to an improved quality of life
for women with heavy menstrual bleeding (in particular, an im-
provement in symptoms of dysmenorrhoea).
R E S U L T S
NSAIDs versus placebo
Menstrual blood loss (objective/subjective)
Mean menstrual blood loss was significantly different in the mefe-
namic acid (MFA) group compared to the placebo group in one
small trial with 11 patients (WMD -124 mls, 95% CI -186 to -
62) in the meta-analysis (MBL in the MFA group was 124 mls
less than in the placebo group). There were no other trials with
data suitable for pooling but six crossover trials were identified
which reported a total effect at the end of the study (three tri-
als compared mefenamic acid with placebo, two trials compared
naproxen with placebo and one trial compared different dosages
(600 mg and 1200 mg daily) of ibuprofen with placebo). In five of
the seven post-treatment comparisons, the post-treatment mean
MBL was significantly different from placebo. However, non sig-
nificant results were also reported for low dose ibuprofen versus
placebo (Makarainen 1986) and mefenamic acid versus placebo
(Muggeridge 1983).
A highly significant difference was found inwomens’ perception of
“relief ” (OR0.08, 95%CI 0.03 to 0.18) of heavymenstrual bleed-
ing between mefenamic acid and placebo groups (Grover 1990).
No additional information was made available from the author re-
garding themeasurement of relief of HMB. In one of the crossover
trials not included in the meta-analysis (Ylikorkala 1986), 79% of
patients indicated that naproxen was “better” compared to 21%
who indicated that the placebo treatment was “better” at reducing
their HMB.
Other outcomes
No trials were identified for the meta-analysis to assess number
of days of menstrual bleeding, change in quality of life, patient
adherence and treatment acceptability. In the small van Eijkeren
study, total incidence of adverse events was comparable between
groups, mefenamic acid and placebo (van Eijkeren 1992). Of the
crossover trials identified above, there was no change in dysmenor-
rhoea scores between treatment cycles, mefenamic acid vs placebo,
(Muggeridge 1983), and no differences in the total incidence of
adverse events between treatment cycles, naproxen vs placebo and
ibuprofen vs placebo (Ylikorkala 1986; Makarainen 1986).
NSAIDs versus tranexamic acid
Menstrual blood loss (objective/subjective)
In the one study available for pooling with 48 patients, a weighted
mean difference of 73 ml/cycle (95% CI 22 to 124) was found in
the comparison of mefenamic acid and tranexamic acid (MBL in
the tranexamic acid group was 73 ml less than in the mefenamic
acid group). In the same study, there was no significant difference
between the groups in the womens’ perception of change in their
MBL. In a crossover trial, where data were not suitable for pooling,
meanMBLwas significantly less in the tranexamic acid cycles (155
ml) than in the flurbiprofen cycles (223 ml), p<0.01 (Andersch
1988).
Number of days of menstrual bleeding
In the one study available for pooling, there were no significant
differences between treatment groups.
Other outcomes
No significant differences were found between groups for the out-
comes, change in quality of life and treatment acceptability, al-
though these results were based on only one study. No trials were
identified to assess the other outcomes.
NSAIDs versus ethamsylate
All outcomes, except for MBL measured objectively, were based
on only one study.
Menstrual blood loss (objective/subjective)
No significant differences were found for both objective (two stud-
ies) and subjective measurement (one study) of MBL between the
treatment groups, immediately after the intervention and at longer
follow up (one study).
Number of days of menstrual bleeding
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In the one study available for pooling, no significant differences
were found for this outcome between treatment groups.
Other outcomes
In the one study available for pooling, no significant differences
were found between treatment groups for the secondary outcome,
change in quality of life, but a greater proportion of women found
ethamsylate unacceptable compared to NSAIDs (OR 0.20, 95%
CI 0.07 to 0.61). No trials were identified to assess the other
outcomes.
NSAIDs versus danazol
Menstrual blood loss (objective)
Reduction of HMB was significantly greater in the danazol group
(WMD 45 ml/cycle, 95% CI 19 to 71). No trials were identified
which assessed womens’ perception of MBL after treatment.
Number of days of menstrual bleeding
The number of days of menstrual bleeding was significantly less
in the danazol compared to the mefenamic acid groups (WMD
1.03, 95% CI 0.26 to 1.80).
Other outcomes
No significant differences were found for the outcomes, change
in quality of life and treatment acceptability between groups, al-
though these results were based on one study with 40 patients. In
this same study, the risk of adverse events was significantly less in
the mefenamic acid group (OR 0.17, 95% CI 0.05 to 0.6).
NSAIDs versus oral progestogen (luteal phase)
Two studies assessedMBL and duration of bleeding and one study
with 35 patients assessed adherence and adverse events. No signif-
icant differences were found for any outcomes.
NSAIDs versus progesterone releasing IUS
Reduction ofHMBwas not significantly different between groups
in one small trial with 16 patients but the number of days of
menstrual bleeding was significantly longer in patients with the
progesterone releasing IUS.
NSAIDs versus oral contraceptive pill
In the one study with data suitable for pooling (26 patients), no
significant differences were found in the objective measurement of
MBLbetween treatment groups.Noother outcomeswere assessed.
Mefenamic acid versus naproxen
No significant differences were found in the objective measure-
ment of MBL (two studies) and total incidence of adverse events
between treatment groups (one study), but the risk of gastroin-
testinal effects was significantly less in the mefenamic acid group
when compared with the naproxen group in one study with 35
patients (OR 0.24, 95% CI 0.06 to 0.87).
D I S C U S S I O N
Assessment of menstrual blood loss is difficult because of cycle to
cycle variation in women (Haynes 1977). Haynes found that cy-
cle-to-cycle variation was greater in patients with heavy menstrual
bleeding (39 to 271ml) than in womenwith normalmenses. Con-
sequently, trials were included in this review only if MBL (mea-
sured objectively) was greater than 80ml/cycle for 2 ormore cycles
prior to the intervention although trials were also included where
women had a subjective complaint of heavy menstrual bleeding.
The alkaline haematin extraction method is the most commonly
used objective method for assessment of blood loss and is used as
the standard but a woman’s own perception of her MBL is also
important in the evaluation of effectiveness of treatment on MBL
and so a woman’s subjective assessment is also a valid assessment
tool. However, many women who seek medical help for heavy
menstrual bleeding will have normal blood loss (Haynes 1977;
Fraser 1984) and results from one RCT have suggested that there
is little response to therapy in women with MBL <35 ml (Fraser
1981). Since a proportion of the study participants with a com-
plaint of heavy menstrual bleeding had normal menstrual blood
loss, it is likely that some reported differences between treatment
and placebo groups have been underestimated.
The clinical differences between individual NSAID preparations
have not been previously explored thoroughly in randomised stud-
ies. Two studies in this review compared mefenamic acid with
naproxen and no differences were found in post-treatment men-
strual blood loss or incidence of adverse events although women
treated with mefenamic acid were less likely to have gastro-intesti-
nal effects. This latter finding, however, based on only one trial, is
not supported by RCTs where NSAIDs are given for other medical
conditions.
Although data comparing different types of NSAIDs were lim-
ited, there was no suggestion of differential efficacy, so in line with
the widely accepted assumption that NSAIDs have similar clini-
cal efficacy, studies comparing different NSAIDs with placebo or
other treatments were combined. Evidence from the one trial in
themeta-analysis and five of the six crossover studies confirms that
NSAIDs are more effective than placebo in reducing MBL. The
quality of the only study in the meta-analysis, however, was not
high; 42% of randomised patients dropped out and the analysis
was not intention to treat. A highly significant difference between
NSAIDs and placebo in reduction of MBL is also perceived by the
patients in one study which recorded the proportion of patients
whowere relieved of their heavymenstrual bleeding as the primary
outcome.
In the comparisons of NSAIDs as a group with other medical
treatments, both tranexamic acid and danazol were more effec-
tive than any of the NSAIDs in reducing MBL. Results from the
only study in the meta-analysis assessing the effect on MBL of
NSAIDs vs tranexamic acid were confirmed by a crossover trial
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(Andersch 1988). A significant reduction was also found in the
meta-analysis of NSAIDs vs danazol in two included studies; the
third study (Cameron 1987) had incomparable groups at baseline
with a significantly higher (almost double) pre-treatment MBL in
the danazol group and the results must be regarded with caution.
There were no significant differences in reduction of MBL in the
comparisons of NSAIDs with ethamsylate, oral progestogen given
during the luteal phase, the progesterone releasing IUS and the
oral contraceptive pill, although the trend in the mefenamic acid
vs ethamsylate comparison and the mefenamic acid vs oral pro-
gestogen comparison suggested that mefenamic acid may be more
effective (p=0.0524; p=0.0562). More studies comparing these
treatments are needed.
In the comparisons of NSAIDs with other medical treatment, the
number of days of menstrual bleeding was significantly shorter
with danazol treatment and significantly longer with the proges-
terone releasing IUS although this latter result was based on only
one small trial. This outcome was not compared with oral contra-
ceptive treatment.
Incidence of adverse events was significantly more likely under
danazol treatment. Although acceptability of treatment did not
differ between danazol and mefenamic acid therapy ( 50% vs 47%
refused to continue), the reasons given were not similar. 80% of
this group of danazol patients refused to continue because of ad-
verse effects but 100% of the mefenamic acid group unwilling to
continue were unhappy about the lack of efficacy of their treat-
ment. A significantly greater proportion of women in the etham-
sylate group compared to women in the NSAID group (MFA)
found their treatment unacceptable.
No trials were identified with data on cost or resource use of
NSAID treatments.
The studies included in this review have examined effects over
two or three menstrual cycles of treatment and one study with
unpublished data has assessed effects one month after treatment
was withdrawn. There is no randomised evidence of effects over a
longer period but one observational study has examined the effects
of mefenamic acid in 34 women over a 16 month period and
reported persistent reductions of 25-35% in menstrual blood loss
and improvement in quality of life (Fraser 1983).
Moreover, different dosage regimens for some of the medical ther-
apies were not considered in the included trials. A longer duration
of oral progestogen treatment (from days 5 to 26 of the menstrual
cycle), and longer duration of treatment over a number of cycles
with all medical therapies are necessary to adequately assess the
comparisons considered in this review.
Although 16 trials met the criteria for inclusion, the inadequacies
in some of the studies must be highlighted. The trials were all
small and underpowered and for many outcomes the results were
based on only one trial. Reduction of MBL in two of the nine
trials (Cameron 1987; Hall 1987) that were included in the meta-
analysis was correctly reported as a median and range in the pub-
lications since the distribution of data was positively skewed with
one or more extremely high values. Substitution of the mean for
the median and the estimation of the standard deviation for these
studies has enabled their inclusion in the meta-analysis but sensi-
tivity analysis with and without the inclusion of the Cameron trial
has not altered results. The Hall study was the only trial compar-
ing MBL after treatment with two NSAIDs, mefenamic acid and
naproxen. The Mann-Whitney U test reported in the publication
of the trial agreed with the results of the meta-analysis finding no
significant difference between the groups.
Two of the included trials had incomparable groups at baseline
(Chamberlain 1991; Cameron 1987) but sensitivity analysis indi-
cated that their inclusion in themeta-analysis did not substantially
alter the results.
Assessments of carryover effects were made in two trials (Fraser
1981; Hall 1987). Fraser found in his crossover trial of mefenamic
acid and placebo, somewhat surprisingly, that the MBL during
placebo cycles was greater (but not significantly) in the group that
took mefenamic acid first. Of considerable interest was the finding
that blood loss in the mefenamic acid cycles was significantly less
(p<0.01) when placebo was taken first, so that mefenamic acid ap-
peared to have a greater beneficial effect when taken after placebo.
There was evidence of a small carryover effect but this did not
reach statistical significance. Hall also tested for carryover effects
but none were found (p=0.96). It is generally accepted that men-
strual blood loss returns to baseline levels very quickly after med-
ical treatment is withdrawn and so the results from the crossover
trials were unlikely to be affected by carryover effects.
In spite of the limited data, it appears that NSAIDs are more effec-
tive than placebo but less effective than tranexamic acid or danazol
in reducing heavy menstrual bleeding. However, adverse events
are more frequent under danazol therapy than NSAID therapy.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The review provides limited evidence of the efficacy of NSAIDs
(of which the most commonly studied is mefenamic acid) as a
treatment for reducing heavy menstrual bleeding in women with
menorrhagia. The efficacy of NSAIDs, however is superseded by
both danazol and tranexamic acid. Other medical treatments ap-
pear to be similarly effective compared to NSAIDs, although there
is a suggestion that mefenamic acid may be more effective than
either ethamsylate or oral progestogen. Danazol also reduces the
number of days of menstrual bleeding but is more likely to cause
adverse events when compared to NSAIDs. Gastro-intestinal ef-
5Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
fects, which are often found with NSAID treatment, are less likely
with mefenamic acid than naproxen.
It is important to emphasize that a proportion of women with a
convincing history of menorrhagia may not have excessive bleed-
ing as defined by the alkaline haematin method. Treatments used
to reduce blood loss in these women are not likely to be as effec-
tive.
The results of the review underscore the multiple assessments that
are required in the evaluation of an optimum treatment. Efficacy is
only one of these; other factors such as cost, convenience, beneficial
and adverse effects on symptoms are also required.
Implications for research
Since mefenamic acid has been most commonly studied, further
RCTs are required to compare individual NSAIDs so that the
optimum treatment can be identified. One of the excluded trials
(Vargyas 1987) reported a greater percentage reduction from base-
line MBL in women using another fenamate, meclofenamic acid,
when compared to other studies assessing mefenamic acid.
Becausemany of the analyses contained only one RCT, some of the
comparisons were not able to be assessed thoroughly, in particular,
the effects of NSAIDs on dysmenorrhoea, adherence to and ac-
ceptability of treatment and incidence of adverse events. However,
since NSAIDs are less efficacious than a number of other medical
therapies, further RCTs are not likely to significantly change the
findings in this review. Future studies comparing treatments for
heavy menstrual bleeding should consider giving a longer dura-
tion of treatment over a number of cycles and a regimen of oral
progestogen given during three of the four weeks of the cycle to
adequately assess comparative effects between medical treatments.
A C K N OW L E D G E M E N T S
The authors acknowledge the helpful comments of those who ref-
ereed previous versions of this review. Special thanks are due toMs
Ruth Jepson, Review Group Coordinator, for her professionalism
and help with the inevitable problems that arise, to Mrs Sue Fur-
ness, Trials Search Coordinator, for her assistance with identifying
trials and to Mrs Sue Hall, Secretary of the Review Group, for
her secretarial help. The authors would also like to acknowledge
the input of the Consumer Network who wrote a synopsis for the
review. This synopsis has been added by the principal author with
minor editing.
R E F E R E N C E S
References to studies included in this review
Andersch 1988 {published data only}
∗ Andersch B, Milsom I, Rybo G. An objective evaluation
of flurbiprofen and tranexamic acid in the treatment of
idiopathic menorrhagia. Acta Obstetricia et Gynecologica
Scandinavica 1988;67:645–48.
Milsom I, Andersson K, Andersch B, Rybo G. A comparison
of flurbiprofen, tranexamic acid, and a levonorgestrel-
releasing intrauterine contraceptive device in the treatment
of idiopathic menorrhagia. American Journal of Obstetrics
and Gynecology 1991;164:879–883.
Bonnar 1996 {published data only}
Bonnar J, Sheppard BL. Treatment of menorrhagia during
menstruation: randomised controlled trial of ethamsylate,
mefenamic acid, and tranexamic acid. BMJ 1996;313:
579–582.
Cameron 1987 {published data only}
Cameron IT. Dysfunctional uterine bleeding. Bailliere’s
Clinical Obstetrics and Gynaecology 1989;2:315–327.
∗ Cameron IT, Leask R, Kelly RW, Baird DT. The
effects of danazol, mefenamic acid, norethisterone
and a progesterone-impregnated coil on endometrial
prostaglandin concentrations in women with menorrhagia.
Prostaglandins 1987;34:99–110.
Cameron 1990 {published data only}
∗ Cameron IT, Haining R, Lumsden MA, Thomas VR,
Smith SK. The effects of mefenamic acid and norethisterone
on measured menstrual blood loss. Obstetetrics & Gynecology
1990;76:85–88.
Smith SK, Haining RH, Reed-Thomas V, Cameron IT. The
diagnosis and treatment of menorrhagia (abstract). Silver
Jubilee British Congress of Obstetrics and Gynaecology
1989:62.
Chamberlain 1991 {published and unpublished data}
Chamberlain G. Comparing treatments for menorrhagia.
Nursing Times 1992;88:46.
Chamberlain G, Freeman R, Price F, Kennedy A, Green D,
Eve L. A comparative study of ethamsylate and mefenamic
acid in dysfunctional uterine bleeding. British Journal of
Obstetrics and Gynaecology 1991;98:707–711.
∗ Chamberlain G, Freeman R, Price F, Kennedy A, Green D,
Eve L. Raw data from RCT. Lorex Synthelabo Laboratory
in UK.
Dockeray 1989 {published data only}
Dockeray CJ, Sheppard BL, Bonnar J. Comparison between
mefenamic acid and danazol in the treatment of established
menorrhagia. Br J Obstets Gynaecol 1989;96:840–844.
Fraser 1981 {published data only}
Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J,
Markham R. Efficacy of mefenamic acid in patients with
6Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
a complaint of menorrhagia. Obstets Gynaecol 1981;58(5):
543–551.
Fraser 1991 {published data only}
Fraser IS, McCarron G. Randomised trial of 2 hormonal
and 2 prostaglandin-inhibiting agents in women with a
complaint of menorrhagia. Aust NZ J Obstet Gynaecol 1991;
31(1):66–70.
Grover 1990 {published data only}
Grover V, Usha R, Gupta U, Kalra S. Management
of cyclical menorrhagia with prostaglandin synthetase
inhibitor. Asia-Oceania J Obstet Gynaecol 1990;16:255–259.
Hall 1987 {published data only}
Hall P, MacLachlan N, Thorn N, Nudd MWE, Taylor
CG, Garrioch DB. Control of menorrhagia by the cyclo-
oxygenase inhibitors naproxen sodium and mefenamic acid.
Brit J Obstet Gynaecol 1987;94:554–558.
Makarainen 1986 {published data only}
Makarainen L, Ylikorkala O. Primary and myoma-
associated menorrhagia: role of prostaglandin and effects of
ibuprofen. Brit J Obstet Gynaecol 1986;93:974–978.
Muggeridge 1983 {published data only}
Muggeridge J, Elder MG. Mefenamic acid in the treatment
of menorrhagia. Res Clin Forums 1983;5:83–88.
Rybo 1981 {published data only}
Nygren KG, Rybo G. Prostaglandins and menorrhagia. Acta
Obstet Gynecol Scand Suppl 1983;113:101–103.
∗ Rybo G, Nilsson S, Sikstrom B, Nygren KG. Naproxen in
menorrhagia (letter). Lancet 1981;March:608–609.
Tsang 1987 {published data only}
Tsang BK, Domingo MT, Spence JEH, Garner PR,
Dudley DK, Oxorn H. Endometrial prostaglandins and
menorrhagia: influence of a prostaglandin synthetase
inhibitor in vivo. Can J Physiol Pharmacol 1987;65:
2081–2084.
van Eijkeren 1992 {published data only}
van Eijkeren MA, Christiaens GCML, Geuze HJ, Haspels
AA, Sixma JJ. Effects of mefenamic acid on menstrual
hemostasis in essential menorrhagia. Am J Obstet Gynecol
1992;166:1419–28.
Ylikorkala 1986 {published data only}
Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but
not fibromyoma-induced menorrhagia. Obstets Gynaecol
1986;68:10–12.
References to studies excluded from this review
Martinez 1979
∗ Martinez Alcala FO, Casanova Alvarez N, Manzanilla
Sevilla R, Gonzalez Iniguez R, Martinez Reyes y P. Efficacy
and tolerability of mefenamic acid in dysfunctional uterine
bleeding [Eficacia y tolerabilidad del acido mefenamico en
la hipermenorrea disfuncional]. Prensa Med Mex 1979;44
(11-12):295–98.
Vargyas 1987
Vargyas JM, Campeau JD, Mishell DR. Treatment of
menorrhagia with meclofenamate sodium. Am J Obstet
Gynecol 1987;157:944–50.
Additional references
Anderson 1976
Anderson AB, Haynes PJ, Guillebaud J, Turnbull AC.
Reduction of menstrual blood-loss by prostaglandin-
synthetase inhibitors. Lancet 1976;1(7963):774–6.
Bradlow 1992
Bradlow J, Coulter A, Brooks P. Patterns of referral. Oxford:
Oxford Health Services Research Unit, 1992.
Chimbira 1980
Chimbira TH, Anderson ABM, Turnbull AC. Relation
between measured menstrual blood loss and patient’s
subjective assessment of loss, duration of bleeding, number
of sanitary towels used, uterine weight and endometrial
surface area. Br J Obstet Gynaecol 1980;87:603–609.
Clarke 1995
Clarke A, Black N, Rowe P, Mott S, Howie K. Indications
for and outcomes of total abdominal hysterectomy for
benign disease: a prospective cohort study. Br J Obstet
Gynaecol 1995;102:611–20.
Cole 1971
Cole S, Billewicz W, Thomson A. Sources of variation in
menstrual blood loss. J Obstet Gynaecol Brit Commonw
1971;78(10):933–39.
Fraser 1981
Fraser IS, Pearse C, Shearman RP, Elliott PM, McIlveen J,
Markham R. Efficacy of mefenamic acid in patients with
a complaint of menorrhagia. Obstets Gynecol 1981;58:
543–551.
Fraser 1983
Fraser IS, McCarron G, Markham R, Robinson M, Smyth
E. Long term treatment of menorrhagia with mefenamic
acid. Obstet Gynaecol 1983;61:109–112.
Fraser 1984
Fraser IS, McCarron G, Markham R. A preliminary study
of factors influencing perception of menstrual blood loss
volume. Am J Obstet Gynecol 1984;149:788–793.
Gath 1982
Gath D, Cooper P, Day A. Hysterectomy and psychiatric
disorder. Levels of psychiatric morbidity before and after
hysterectomy. Int J Psych 1982;140:335–340.
Hagenfeldt 1987
Hagenfeldt K. The role of prostaglandins and allied
substances in uterine haemostasis. Contraception 1987;36
(1):23–35.
Hallberg 1966
Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual
blood loss - a population study. Acta Obstet Gynecol Scand
1966;45:320–351.
7Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Haynes 1977
Haynes PJ, Hodgson H, Anderson AB, Turnbull
AC. Measurement of menstrual blood loss in patients
complaining of menorrhagia. Br J Obstet Gynaecol 1977;84
(10):763–8.
Higham 1990
Higham JM, O’Brien PMS, Shaw RW. Assessment of
menstrual blood loss using a pictorial chart. Br J Obstet
Gynaecol 1990;97:734–39.
Newton 1977
Newton J, Barnard G, Collins W. A rapi method for
measuring menstrual blood loss using automatic extraction.
Contraception 1977;16:269–82.
Rees 1987
Rees MCP, DiMarzo V, Tippins JR, et al.Leukotriene
release by endometrium and myometrium throughout the
menstrual cycle in dysmenorrhoea and menorrhagia. J
Endocrinol 1987;113:291–5.
Smith 1981
Smith SK, Abel MH, Kelly RW, Baird DT. Prostaglandin
synthesis in the endometrium of women with ovular
dysfunctional uterine bleeding. Br J Obstet Gynaecol 1981;
88:434–442.
Vessey 1992
Vessey M, Villard-Mackintosh L, McPherson K, Coulter A,
Yeates D. The epidemiology of hysterectomy: findings in a
large cohort study. Br J Obstet Gynaecol 1992;99(5):402–7.
Willman 1976
Willman EA, Collins WD, Clayton SC. Studies on the
involvement of prostaglandins in uterine symptomatology
and pathology. Br J Obstet Gynaecol 1976;83:337–341.
Wood 1980
Wood C, Jakubowicz D. The treatment of premenstrual
symptoms with mefenamic acid. Br J Obstet Gynaecol 1980;
87(7):627–30.
∗ Indicates the major publication for the study
S O U R C E S O F S U P P O R T
External sources of support
• Heatlth Research Council, Auckland NEW ZEALAND
Internal sources of support
• Department of Obstetrics and Gynaecology, University of Auckland, Auckland NEW ZEALAND
N O T E S
An updated search was performed in September and October 2001 but no new eligible trials were identified.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Inflammatory Agents, Non-Steroidal [∗therapeutic use]; Dysmenorrhea [drug therapy]; Menorrhagia [∗drug therapy]; Random-
ized Controlled Trials
8Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
MeSH check words
Female; Humans
9Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
